Author + information
- Rahul Pidikiti,
- Nada Esa,
- Menhel Kinno,
- Jeanine A. Ward,
- Jane E. Freedman,
- John Keaney,
- Victor Ambros and
- David McManus
MicroRNAs (miRNAs) regulate gene expression in patient with cardiovascular disease (CVD). Up-regulation of certain miRNAs in atrial myocytes enhance vulnerability to atrial fibrillation (AF). It remains unclear whether or not circulating cardiac-specific miRNAs vary between individuals with atrial fibrillation (AF) and those in sinus rhythm (SR). Our aim is to test the hypothesis that levels of cardiac-specific plasma miRNAs would differ between patients with AF and controls with no history of AF.
17 patients with paroxysmal or persistent AF and 24 hospitalized patients in SR with no history of AF were recruited. 94 plasma miRNAs were selected based on their association with processes implicated in processes underlying AF. High-throughput quantitative polymerase chain reaction systems were used to quantify plasma miRNA levels.
We found a > 2 fold change in the expression of 14 miRNAs, several of which have been implicated in cardiovascular remodeling and other forms of CVD (Figure 1). Levels of miR-7, miR-208, and miR-302b were significantly up- or down-regulated in AF patients relative to controls (p<0.05) and levels of miR-218 varied by greater than 20-fold (p=0.095).
Our data suggest that circulating miRNA profiles may be useful in identifying patients with AF. Further investigations are needed to replicate our findings in larger patient samples and explore the mechanistic implications of our findings.
Poster Sessions, Expo North
Saturday, March 09, 2013, 3:45 p.m.-4:30 p.m.
Session Title: Arrhythmias: AF/SVT IV
Abstract Category: 4. Arrhythmias: AF/SVT
Presentation Number: 1152-55
- 2013 American College of Cardiology Foundation